1. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. Issue 12 (December 2016) Authors: Popat, Rakesh; Brown, Sarah R; Flanagan, Louise; Hall, Andrew; Gregory, Walter; Kishore, Bhuvan; Streetly, Matthew; Oakervee, Heather; Yong, Kwee; Cook, Gordon; Low, Eric; Cavenagh, Jamie Journal: Lancet Issue: Volume 3:Issue 12(2016) Page Start: e572 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial. (15th August 2020) Authors: Atkin, Catherine; Iqbal, Gulnaz; Planche, Tim; Pratt, Guy; Yong, Kwee; Wood, Jill; Raynes, Kerry; Low, Eric; Higgins, Helen; Neal, Richard D.; Dunn, Janet; Drayson, Mark T; Bowcock, Stella Journal: British journal of haematology Issue: Volume 192:Number 6(2021) Page Start: 997 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Epidemiology of cardiomyopathies and incident heart failure in a population-based cohort study. Issue 17 (30th December 2021) Authors: Brownrigg, Jack RW; Leo, Vincenzo; Rose, Joel; Low, Eric; Richards, Sarah; Carr-White, Gerry; Elliott, Perry M Journal: Heart Issue: Volume 108:Issue 17(2022) Page Start: 1383 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial). (20th August 2018) Authors: Popat, Rakesh; Brown, Sarah R.; Flanagan, Louise; Hall, Andrew; Gregory, Walter; Kishore, Bhuvan; Streetly, Matthew; Oakervee, Heather; Yong, Kwee; Cook, Gordon; Low, Eric; Cavenagh, Jamie Journal: British journal of haematology Issue: Volume 185:Number 3(2019) Page Start: 573 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Guidelines for screening and management of late and long‐term consequences of myeloma and its treatment. (20th January 2017) Authors: Snowden, John A.; Greenfield, Diana M.; Bird, Jennifer M.; Boland, Elaine; Bowcock, Stella; Fisher, Abigail; Low, Eric; Morris, Monica; Yong, Kwee; Pratt, Guy Journal: British journal of haematology Issue: Volume 176:Number 6(2017) Page Start: 888 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Individual Trade‐Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma. (27th October 2017) Authors: Postmus, Douwe; Richard, Sarah; Bere, Nathalie; van Valkenhoef, Gert; Galinsky, Jayne; Low, Eric; Moulon, Isabelle; Mavris, Maria; Salmonsson, Tomas; Flores, Beatriz; Hillege, Hans; Pignatti, Francesco Journal: Oncologist Issue: Volume 23:Number 1(2018) Page Start: 44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Letter of support from Eric Low, Director, Eric Low Consulting, Edinburgh, UK. (29th January 2021) Authors: Low, Eric Journal: International journal of technology assessment in health care Issue: Volume 37:Number 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Issue 12 (December 2019) Authors: Drayson, Mark T; Bowcock, Stella; Planche, Tim; Iqbal, Gulnaz; Pratt, Guy; Yong, Kwee; Wood, Jill; Raynes, Kerry; Higgins, Helen; Dawkins, Bryony; Meads, David; Hulme, Claire T; Monahan, Irene; Karunanithi, Kamaraj; Dignum, Helen; Belsham, Edward; Neilson, Jeff; Harrison, Beth; Lokare, Anand; Cam... Journal: Lancet oncology Issue: Volume 20:Issue 12(2019) Page Start: 1760 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. OP84 Cost Consequence Analysis: A Potential Framework To Incorporate Patient Preferences Into Health Technology Assessment And Reimbursement Decisions. (23rd December 2022) Authors: Whitty, Jennifer; Marsh, Kevin; Low, Eric; Shah, Koonal; Dzingina, Mendwas Journal: International journal of technology assessment in health care Issue: Volume 38(2022)Supplement 1 Page Start: S31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Optimizing the management of patients with spinal myeloma disease. (17th July 2015) Authors: Molloy, Sean; Lai, Maggie; Pratt, Guy; Ramasamy, Karthik; Wilson, David; Quraishi, Nasir; Auger, Martin; Cumming, David; Punekar, Maqsood; Quinn, Michael; Ademonkun, Debo; Willis, Fenella; Tighe, Jane; Cook, Gordon; Stirling, Alistair; Bishop, Timothy; Williams, Cathy; Boszczyk, Bronek; Reynolds,... Journal: British journal of haematology Issue: Volume 171:Number 3(2015:Nov.) Page Start: 332 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗